Late mortality after dexrazoxane treatment: A report from the Children's Oncology Group

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2639-2645

  Chow, Eric J ^a   Asselin, Barbara L ^b   Schwartz, Cindy L ^c   Doody, David R ^a   Leisenring, Wendy M ^a   Aggarwal, Sanjeev ^d   Baker, K Scott ^a   Bhatia, Smita ^e   Constine, Louis S ^b   Freyer, David R ^f   Lipshultz, Steven E ^d   Armenian, Saro H ^g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RAZOXANE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CARDIOMYOPATHY; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HODGKIN DISEASE; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; TREATMENT RESPONSE; ADULT; DRUG INTERACTION; MORTALITY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEXRAZOXANE; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HODGKIN DISEASE; HUMANS; INFANT; MALE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84940502191     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4473     Document Type: Article

References (27)

1. Lipshultz SE, Adams MJ, Colan SD, et al: Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions - A scientific statement from the American Heart Association. Circulation 128:1927-1995, 2013
2. Armstrong GT, Kawashima T, Leisenring W, et al: Aging and risk of severe, disabling, life-threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol 32:1218-1227, 2014
3. van Dalen EC, Caron HN, Dickinson HO, et al: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 6:CD003917, 2011
4. Armenian SH, Gelehrter SK, Chow EJ: Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer. Cardiol Res Pract 2012:713294, 2012
5. Hasinoff BB, Hellmann K, Herman EH, et al: Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28, 1998
6. Wexler LH, Andrich MP, Venzon D, et al: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372, 1996
7. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145-153, 2004
8. Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961, 2010
9. Asselin BL, Devidas M, Wang C, et al: Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: A randomized study by the Children's Oncology Group (POG 9404). Blood 118:874-883, 2011
10. Schwartz CL, Constine LS, Villaluna D, et al: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 114:2051-2059, 2009
11. Tebbi CK, Mendenhall NP, London WB, et al: Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group. Pediatr Blood Cancer 59:1259-1265, 2012
12. Asselin B, Devidas M, Zhou T, et al: Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). J Clin Oncol 30:607s, 2012 (suppl; abstr 9504)
13. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25:493-500, 2007
14. Hensley ML, Hagerty KL, Kewalramani T, et al: American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 27:127-145, 2009
15. European Medicines Agency: June 24, 2011, Press Release: European Medicines Agency recommends restricting the use of dexrazoxane-containing medicines. http://www.ema.europa.eu/ema/index.jsp?curlo=pages/news-and-events/news/2011/06/news-detail-001288.jsp&mid=WC0b01ac058004d5c1
16. Walker DM, Fisher BT, Seif AE, et al: Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr Blood Cancer 60:616-620, 2013
17. National Center for Health Statistics: National Death Index user's guide. Hyattsville, MD, 2013. http://www.cdc.gov/nchs/data/ndi/NDI-Users-Guide.pdf
18. Rogot E, Sorlie P, Johnson NJ: Probabilistic methods in matching census samples to the National Death Index. J Chronic Dis 39:719-734, 1986
19. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data (ed 2). Hoboken, NJ, John Wiley and Sons, 2002
20. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
21. Chow EJ, Chen Y, Kremer LC, et al: Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 33:394-402, 2015
22. Bhatia S: Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 40:666-675, 2013
23. Vrooman LM, Neuberg DS, Stevenson KE, et al: The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 47:1373-1379, 2011
24. Seif AE, Walker DM, Li Y, et al: Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer 62:704-709, 2015
25. Mertens AC, Liu Q, Neglia JP, et al: Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 100:1368-1379, 2008
26. van Dalen EC, van der Pal HJ, Caron HN, et al: Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 4:CD005008, 2009
27. van Dalen EC, Michiels EM, Caron HN, et al: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 5:CD005006, 2010